Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China's FDA Issues Revised GMP Draft Guideline Following Industry Comments; Expects Compliance To Come In Stages

This article was originally published in The Pink Sheet Daily

Executive Summary

"It will be interesting to see how much of a grace period is given for manufacturers to meet standards, or whether certain manufacturers will be 'grandfathered' under old rules," industry consultant says.

You may also be interested in...



USP Tightens Supply Chain Controls with Risk-Based Vendor Qualification; Aims To Prevent New Heparin Crisis

The U.S. Pharmacopeia is taking a forward-looking, risk-based approach to protecting the supply chain for biological drug products from intentional and unintentional adulteration, even as it adds testing requirements aimed at preventing a new heparin crisis

China Releases Strictest Ever GMP Draft Guidelines; Laxer Standards Urged For Local Companies

SHANGHAI - China's State FDA recently published a new draft version of Good Manufacturing Practice guidelines for pharmaceuticals on its website for public comment

China Implements New Quality System To Strengthen Drug Safety; Puts Legal Onus On Drug Quality Attorneys

SHANGHAI - China's State FDA launched a new quality system April 10 that requires companies to assign responsibility for drug manufacturing to a drug quality administrator. The move builds accountability into drug manufacturers' systems

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068891

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel